Related Experiment Videos

Effects of Nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated

Alexandros P Patrianakos1, Fragiskos I Parthenakis, Hercules E Mavrakis

  • 1Cardiology Department, University Hospital of Heraklion, Crete, Greece. cardio@med.uoc.gr

Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|June 29, 2005
PubMed

Insights

Nebivolol improves heart function in non-ischaemic dilated cardiomyopathy patients, reducing symptoms and improving ejection fraction. However, it may decrease maximal exercise duration.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Non-ischaemic dilated cardiomyopathy (NIDC) affects left ventricular (LV) function and exercise capacity.
  • Assessing Nebivolol's impact on NIDC patients is crucial for treatment strategies.

Purpose of the Study:

  • To evaluate the effects of Nebivolol on left ventricular (LV) function and exercise capacity in patients with NIDC.
  • To determine the safety and tolerability of Nebivolol in this patient population.

Main Methods:

  • A double-blind, randomized trial involving 60 NIDC patients (NYHA class II-III, LV ejection fraction < 45%).
  • Patients received either Nebivolol (5 mg target dose) or placebo for 3 months.
  • Evaluations included echocardiography and exercise tests.

Main Results:

  • Nebivolol significantly improved NYHA class, reduced resting heart rate, and lowered systolic and diastolic blood pressure compared to placebo.
  • Left ventricular ejection fraction increased, and LV end-systolic volume decreased in the Nebivolol group.
  • While diastolic function improved, maximal exercise duration and heart rate were reduced with Nebivolol treatment.

Conclusions:

  • Nebivolol demonstrates safety and tolerability in NIDC patients.
  • The drug effectively improves NYHA class and both systolic and diastolic LV function.
  • A potential drawback is the observed reduction in maximal exercise duration.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...